-
公开(公告)号：US20200291104A1
公开(公告)日：2020-09-17
申请号：US16063133
申请日：2016-12-14
Applicant: UCB BIOPHARMA SPRL
Inventor： Ralph Adams , Pallavi Bhatta , Emma Dave , Sam Philip Heywood , Dave Paul Humphreys , Diane Marshall , Daniel John Lightwood
Abstract: The invention relates to antibody molecules having specificity for TNF alpha, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：US20190161536A1
公开(公告)日：2019-05-30
申请号：US16197066
申请日：2018-11-20
Inventor： Gökhan S. Hotamisligil , Mehmet F. Burak , Feyza Engin , Scott B. Widenmaier , Elisabeth Helen Roberts , Adrian Richard Moore , Carl Brendan Doyle , Ralph Adams , Karine Jeannine Madeleine Hervé , Shauna Mhairi Wales , Kerry Louise Tyson
Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
-
公开(公告)号：US09873735B2
公开(公告)日：2018-01-23
申请号：US14697142
申请日：2015-04-27
Applicant: UCB Biopharma SPRL
Inventor： Ralph Adams , Pallavi Bhatta , Sam Philip Heywood , David Paul Humphreys
IPC: A61K39/395 , C07K16/18 , C07K16/28 , A61K39/00
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K16/2878 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/624 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
Patent Agency Ranking
公开(公告)号：US20160031974A1
公开(公告)日：2016-02-04
申请号：US14697142
申请日：2015-04-27
Applicant: UCB Biopharma SPRL
Inventor： Ralph Adams , Pallavi Bhatta , Sam Philip Heywood , David Paul Humphreys
IPC: C07K16/18 , A61K39/395 , C07K16/28
CPC classification number: C07K16/18 , A61K39/3955 , A61K2039/505 , C07K16/2866 , C07K16/2878 , C07K2317/31 , C07K2317/55 , C07K2317/622 , C07K2317/624 , C07K2317/64 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of human OX40, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
Abstract translation: 本发明涉及对人OX40的抗原决定簇具有特异性的抗体分子，抗体分子的治疗用途以及产生所述抗体分子的方法。
-
15.发明申请公开(公告)号：US20190233530A1
公开(公告)日：2019-08-01
申请号：US16379844
申请日：2019-04-10
Applicant: UCB BIOPHARMA SPRL , BIOGEN MA INC.
Inventor： Linda C. Burkly , Janine L. Ferrant-Orgettas , Ellen A. Garber , Yen-Ming Hsu , Lihe Su , Frederick R. Taylor , Ralph Adams , Derek Thomas Brown , Andrew George Popplewell , Martyn Kim Robinson , Anthony Shock , Kerry Louise Tyson
IPC: C07K16/28 , A61K39/395 , A61K45/06
CPC classification number: C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
-
公开(公告)号：US10160798B2
公开(公告)日：2018-12-25
申请号：US15143162
申请日：2016-04-29
Inventor： Gökhan S. Hotamisligil , Mehmet F. Burak , Feyza Engin , Scott B. Widenmaier , Elisabeth Helen Roberts , Adrian Richard Moore , Carl Brendan Doyle , Ralph Adams , Karine Jeannine Madeleine Hervé , Shauna Mhairi Wales , Kerry Louise Tyson
Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
-
公开(公告)号：US10023631B2
公开(公告)日：2018-07-17
申请号：US15795874
申请日：2017-10-27
Applicant: UCB Biopharma SPRL
Inventor： Ralph Adams , Pallavi Bhatta , Sam Philip Heywood , David Paul Humphreys
Abstract: A serum albumin binding antibody or fragment thereof comprising a heavy chain variable domain having the sequence given in SEQ ID NO: 1 or SEQ ID NO:2 and/or comprising a light chain variable domain having the sequence given in SEQ ID NO:3 or SEQ ID NO:4, in particular comprising a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 1 and SEQ ID NO:3 or a heavy chain variable domain and a light chain variable domain having the sequence given in SEQ ID NO: 2 and SEQ ID NO:4. The disclosure also extends to polynucleotides encoding the antibodies or fragments, vectors comprising same and host cells capable of expressing the polynucleotides. The disclosure further includes pharmaceutical compositions comprising the antibodies or fragments and therapeutic used of any one of the same.
-
公开(公告)号：US09890219B2
公开(公告)日：2018-02-13
申请号：US14706234
申请日：2015-05-07
Applicant: UCB BIOPHARMA SPRL
Inventor： Ralph Adams , Andrew George Popplewell , Stephen Edward Rapecki
IPC: A61K39/395 , C07K16/46 , C07K16/24
CPC classification number: C07K16/468 , A61K39/3955 , C07K16/244 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/565 , C07K2317/76 , C07K2317/90 , C07K2317/92
Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
-
-
-
-
-
-
Search Results
18
records
(took 0.025 seconds)
